Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude …
Jan. 31 Deadline: HIV League Scholarships for Higher Ed Students Living with HIV
Illinois HIV Care Connect Reaches Out to Spanish-Speaking Population on World AIDS Day
SPRINGFIELD, Ill.–Illinois HIV Care Connect today reached out to the Illinois Spanish-speaking population by featuring two organizations that are representative of how Illinois helps this community to prevent and provide care for HIV.
“HIV innovation is occurring among the Spanish-speaking